(Q33375874)

26 July 2017

1 reference

title

Amrubicin for non-small-cell lung cancer and small-cell lung cancer (English)

1 reference

26 July 2017

1 reference

3

Kenji Tamura

1 reference

26 July 2017

Takayasu Kurata

1

1 reference

26 July 2017

Isamu Okamoto

series ordinal

2

1 reference

26 July 2017

Masahiro Fukuoka

series ordinal

4

1 reference

26 July 2017

13 July 2007

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

25

1 reference

26 July 2017

499-504

1 reference

26 July 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-007-9069-0

26 July 2017

0 references

cites work

Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-007-9069-0

In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-007-9069-0

Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-007-9069-0

A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-007-9069-0

Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

21 January 2018

1 reference

12 December 2020

[Phase I study of SM-5887, a new anthracycline derivative]

1 reference

12 December 2020

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

1 reference

12 December 2020

Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin.

1 reference

12 December 2020

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

1 reference

12 December 2020

Phase I and pharmacokinetic study of SM-5887 by 5-day schedule

1 reference

12 December 2020

Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer

1 reference

12 December 2020

Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

12 December 2020

Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

1 reference

12 December 2020

Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer

1 reference

12 December 2020

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

12 December 2020

[Evaluation of amrubicin with a 5 day administration schedule in a mouse model]

1 reference

12 December 2020

Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer

1 reference

12 December 2020

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer

1 reference

12 December 2020

Recurrent small cell lung cancer: update

1 reference

12 December 2020

Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients

1 reference

12 December 2020

10.1007/S10637-007-9069-0

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference